PF-08653944
Sponsors
Pfizer Inc., Pfizer
Conditions
Body WeightDiabetes, Type 2Drug InteractionHealthyNutrition DisordersNutritional and Metabolic DiseasesObesityOvernutrition
Phase 1
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity
CompletedNCT07400679
Start: 2026-02-04End: 2026-07-08Updated: 2026-08-17
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity
Active, not recruitingNCT07508241
Start: 2026-03-31End: 2027-01-27Updated: 2026-07-09
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
RecruitingNCT07519135
Start: 2026-04-15End: 2027-07-09Target: 26Updated: 2026-04-23
Phase 2
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Active, not recruitingNCT07400653
Start: 2026-02-24End: 2028-05-16Updated: 2026-09-08
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
RecruitingNCT07595549
Start: 2026-06-10End: 2028-06-21Target: 954Updated: 2026-09-04
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
Not yet recruitingCTIS2026-525318-75-00
Target: 120Updated: 2026-09-11